Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reexamination Certificate
2007-09-25
2007-09-25
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S489000
Reexamination Certificate
active
10301185
ABSTRACT:
The present invention is directed to a method for delivering agents to the central nervous system by way of a tissue innervated by the trigeminal nerve that is outside the nasal cavity. Such a method of delivery can be useful in the treatment of central nervous system and/or brain disorders.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4464358 (1984-08-01), Cox
patent: 4479932 (1984-10-01), Bodor
patent: 4507391 (1985-03-01), Pukel et al.
patent: 4579858 (1986-04-01), Fernö et al.
patent: 4584278 (1986-04-01), Knauf
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4639437 (1987-01-01), della Valle et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4675287 (1987-06-01), Reisfeld et al.
patent: 4746508 (1988-05-01), Carey et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4822594 (1989-04-01), Gibby
patent: 4895452 (1990-01-01), Yiournas et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4921706 (1990-05-01), Roberts et al.
patent: 5153002 (1992-10-01), McMullen
patent: 5250023 (1993-10-01), Lee et al.
patent: 5624898 (1997-04-01), Frey, II
patent: 5985320 (1999-11-01), Edwards et al.
patent: 6244265 (2001-06-01), Cronk et al.
patent: 0 145 209 (1985-06-01), None
patent: 0 333 574 (1989-09-01), None
patent: 0 351 808 (1990-01-01), None
patent: 0 539 087 (1993-04-01), None
patent: 2 260 329 (1975-09-01), None
patent: 2-214 (1990-01-01), None
patent: 2-78632 (1990-03-01), None
patent: 7-41428 (1995-02-01), None
patent: 2590548 (1996-12-01), None
patent: 2734554 (1998-01-01), None
patent: 1139 444 (1985-02-01), None
patent: WO86/02271 (1986-04-01), None
patent: WO86/04233 (1986-07-01), None
patent: WO88/09171 (1988-12-01), None
patent: WO89/01343 (1989-02-01), None
patent: WO97/49419 (1997-12-01), None
patent: WO98/34645 (1998-08-01), None
Altman, J.,Nature, 1989, vol. 337(688).
Amaducci, L., et al., “Use of Phosphatidylserine in Alzheimer's Disease,”Annals of New York Academy of Science, 1991, pp. 245-249, vol. 640.
Ang et al., “Blood-Cerebrospinal Fluid Barrier to Arginine Vasopressin, Desmopressin and Desglycinamide Arginine-Vasopressin in the Dog,”Journal of Endocrinology, 1982, pp. 319-325, vol. 93.
Aoki et al., “Distribution and Removal of Human Serum Albumin -Technetium 99m Instilled Intranasally,”British Journal of Clinical Pharmacology, 1976, pp. 869-878, vol. 3.
Baker, H., et al.,Experimental Brain Research, 1986, pp. 461-473, vol. 63.
Boies et al.,Fundamentals of Otolaryngology, 1989, pp. 184-185.
Boissière, F., et al., “Decrease of TrkA Messenger RNA Content in Cholinergic Neurons of the Striatum and Basal Forebrain in Alzheimer's Disease,” (date unknown), P03.041.
Bowen, D., et al.,The Lancet, 1979, pp. 11-14.
Broadwell, “Transcytosis of Macromolecules Through the Blood-Brain Barrier: A Cell Biological Perspective and Critical Appraisal,”Acta Neuropathology, 1989, pp. 117-128, vol. 79.
Chase, M., “Nerve- Growth Factors Brighten the Medical Horizon,”The Wall Street Journal, Mar. 12, 1992, pp. B1 and B7.
Chen, X., et al., “Delivery of Nerve Growth Factor to the Brain Via the Olfactory Pathway,”Journal of Alzheimer's Disease, 1998, pp. 35-44, vol. 1.
Chen, X., et al., “Olfactory Route: A New Pathway to Deliver Nerve Growth Factor to the Brain,”Neurobiology of Aging(Suppl. 4S), 1998, Abstract No. 1086.
Chia, L., et al.,Biochimica et Biophysica Acta, 1984, pp. 308-312, vol. 775.
Chien, et al.,Nasal Systemic Drug Delivery, 1989, pp. 18-19, 44-49, 56-59, 82-85, 292-293.
Chien, et al., inCRC Critical Reviews in Therapeutic Drug Carrier Systems, 1987, pp. 67-194, vol. 4.
Chou, K., et al., “Distribution of Antihistamines into the CSF Following Intranasal Delivery”,Biopharmaceutics&Drug Disposition, 1997, pp. 335-346, vol. 18(4), Abstract.
Chou, K., et al., “Lidocaine Distribution into the CNS Following Nasal and Arterial Delivery: A Comparison of Local Sampling and Microdialysis Techniques”,International Journal of Pharmaceutics, 1998, pp. 53-61, vol. 171, Abstract.
Chou, K., et al., “The Distribution of Local Anesthetics into the CSF Following Intranasal Administration,”International Journal of Pharmaceutics, 1998, pp. 137-145, vol. 168.
Clements, J., et al., “Alzheimer Disease and Associated Disorders,” 1990, pp. 35, 37, 39, 41, vol. 4(1).
Clements, J., et al., “Ganglioside Alterations in Alzheimer's Disease and Treatment of Alzheimer's Disease with GM-I,”AHAF Alzheimer's Disease Research Conference, Feb. 17, 1989 (Abstract), 1 pg.
Crook, T., et al.,Psychopharmacology Bulletin, 1992, pp. 61-66, vol. 28(1).
Cummings, J., et al., “Dementia of the Alzheimer Type,”JAGS, 1986, pp. 12-19, vol. 34.
DeMyer, W., “Brainstem and Cranial Nerves,”Neuroanatomy, 1988, pp. 164-1669, John Wiley and Sons, New York.
Dodd and Kelly, “The Brain Stem and Reticular Core,”Trigeminal System, pp. 701-710.
Doty, R.L.,Annals of National Academy of Sciences, 1989, pp. 76-86, vol. 561.
Draghia, R., “Gene Delivery into the Central Nervous System by Nasal Instillation in Rats,”Gene Therapy, 1995, pp. 418-423, vol. 2(6).
Editors,Neurobiology of Aging, 1986, vol. 7(599).
Eisenbarth et al., “Monoclonal Antibody to a Plasma Membrane Antigen of Neurons,”Proceedings of the National Academy of Sciences USA, 1979, pp. 4913-4917, vol. 76.
Emory et al., “Ganglioside Monoclonal Antibody (A2B5) Neurofibrillary Tangles,”Fed. Proceedings, 1986, p. 1728, vol. 45.
Emory et al., “Ganglioside Monoclonal Antibody (A2B5) Neurofibrillary Tangles,”Neurology, 1987, pp. 768-772, vol. 37.
Eppstein et al., “Alternative Delivery Systems for Peptides and Proteins as Drugs,”CRC Critical Reviews in Therapeutic Drug Carrier Systems, 1988, pp. 99-139, vol. 5.
Fabian et al., “Intraneuronal IgG in the Central Nervous System: Uptake by Retrograde Axonal Transport,”Neurology, 1987, pp. 1780-1784.
Fabian, R.,Neurology, 1990, pp. 419-422, vol. 40.
Ferreyra-Moyano, H.,International Journal of Neuroscience, 1989, pp. 157-197, vol. 49.
Fischer, W., et al.,Nature, Sep. 3, 1987, pp. 65-68, vol. 329.
Fredman, P., et al., “Monoclonal Antibody A2B5 Reacts with Many Gangliosides in Neuronal Tissue,”Archives of Biochemistry and Biophysics, 1984, pp. 661-666, vol. 233(2).
Frey II, W., et al., “Delivery of125I-NGF to the Brain Via the Olfactory Route,”Drug Delivery, 1997, pp. 87-92, vol. 4.
Frey II, W., et al., “Research Advances in Alzheimer's Disease Research,”Progress in Clinical Neurosciences, 1988, pp. 287-303, vol. 1.
Frey II, W., et al., “Research Advances in Alzheimer's Disease and Related Disorders,” 1995, pp. 329-335.
Frey II, W., et al., “Alzheimer's Neurofibrillary Tangles Are Labeled by Ganglioside Monoclonal Antibody A2B5,”Alzhemier's Disease: Advance in Basic Research and Therapies, 1987, pp. 411-415.
Friden, P., et al.,Science, Jan. 15, 1993, pp. 373-377, vol. 259.
Galanos, et al., “Preparation and Properties of Antisera Against the Lipid-A Component of Bacterial Lipopolysaccharides,”European Journal of Biochemistry, 1971, pp. 116-122, vol. 24.
Ghanbari, H., et al.,JAMA, Jun. 6, 1990, pp. 2907-2910, vol. 263(21).
Gopinath, et al., “Target Site of Intranasally Sprayed Substances and Their Transport Across the Nasal Mucosa: A New Insight into the Intranasal Route of Drug-Delivery,”Current Therapeutic Research, 1978, pp. 596-607, vol. 23.
Gorio, et al.,Neuroscience, 1983, pp. 417-429, vol. 8.
Gray, H., “The Nervous System: The Cranial Nerve,”Gray's Anatomy, 1977, pp. 725-738, Crown Publishers, Inc.
Graziadei et al., “Neurogenesis and Neuron Regeneration in the Olfactory System of Mammals. I. Morphological Aspects of Differentiation and Structural Organization of the Olfactory Sensory Neurons,”Journal of Neurocytology, 1979, pp. 1-18, vol. 8.
Guthrie, K., et
Frey, II William H.
Thorne Robert Gary
Abrahamson Susan L.
Bergin Denise
Chiron Corporation
Harbin Alisa A.
Kishore Gollamudi S.
LandOfFree
Method for administering agents to the central nervous system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for administering agents to the central nervous system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for administering agents to the central nervous system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3772431